For research use only. Not for therapeutic Use.
Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.
| Catalog Number | I047313 |
| Purity | ≥95% |
| Reference | [1] Herrera AF, et al. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301. |
